|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
US6833349B2
(en)
*
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
DE60219419T2
(de)
|
2001-01-19 |
2007-08-16 |
Ludwig Institute For Cancer Research |
Flt4 (vegfr-3) als ein ziel für krebsdarstellung und anti-krebs-behandlung
|
|
US6734017B2
(en)
|
2001-09-28 |
2004-05-11 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of vascular endothelial growth factor receptor-2 expression
|
|
ATE500842T1
(de)
|
2002-05-04 |
2011-03-15 |
Acorda Therapeutics Inc |
Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
|
|
DK1608685T3
(da)
*
|
2003-03-28 |
2007-06-11 |
Regeneron Pharma |
VEGF antagonister til behandlingen af diabetes
|
|
EP3211084B1
(en)
|
2003-05-16 |
2019-03-27 |
Acorda Therapeutics, Inc. |
Proteoglycan degrading mutants for treatment of cns
|
|
EP2354155B1
(en)
*
|
2003-05-16 |
2017-05-03 |
Acorda Therapeutics, Inc. |
Fusion Proteins for Treatment of CNS
|
|
US7959914B2
(en)
|
2003-05-16 |
2011-06-14 |
Acorda Therapeutics, Inc. |
Methods of reducing extravasation of inflammatory cells
|
|
JP2007529418A
(ja)
*
|
2003-05-28 |
2007-10-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｖｅｇｆアンタゴニストの使用による角膜移植拒絶を処置する方法
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
US7354578B2
(en)
|
2003-06-06 |
2008-04-08 |
Regeneron Pharmaceuticals, Inc. |
Method of tumor regression with VEGF inhibitors
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
*
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
WO2005016369A1
(en)
*
|
2003-08-06 |
2005-02-24 |
Regeneron Pharmaceuticals, Inc. |
Use of a vegf antagonist in combination with radiation therapy
|
|
US8226941B2
(en)
|
2004-05-18 |
2012-07-24 |
Acorda Therapeutics, Inc. |
Methods of purifying chondroitinase and stable formulations thereof
|
|
JP4680997B2
(ja)
*
|
2004-06-08 |
2011-05-11 |
ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド |
血管新生を阻害するキメラタンパク質およびその利用
|
|
JP2008502738A
(ja)
|
2004-06-10 |
2008-01-31 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用
|
|
EP1755645A2
(en)
*
|
2004-06-18 |
2007-02-28 |
Regeneron Pharmaceuticals, Inc. |
Vegf inhibitors for the treatment of malignant pleural effusion
|
|
CN1997386B
(zh)
|
2004-07-30 |
2012-05-30 |
瑞泽恩制药公司 |
通过阻断vegf介导的活性来治疗i型糖尿病的方法
|
|
DE602005021811D1
(de)
*
|
2004-09-13 |
2010-07-22 |
Genzyme Corp |
Multimere konstrukte
|
|
FR2878749B1
(fr)
*
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
|
US7303748B2
(en)
|
2005-02-02 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a VEGF inhibitor
|
|
ES2633574T3
(es)
|
2005-03-25 |
2017-09-22 |
Regeneron Pharmaceuticals, Inc. |
Formulaciones de antagonistas de VEGF
|
|
WO2007038548A2
(en)
|
2005-09-26 |
2007-04-05 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase abci mutants
|
|
JP5489465B2
(ja)
†
|
2005-12-16 |
2014-05-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
|
|
FR2895258B1
(fr)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
|
CN100502945C
(zh)
*
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
PT2944306T
(pt)
|
2006-06-16 |
2021-02-15 |
Regeneron Pharma |
Formulações antagonistas de vegf adequadas para administração intravitreal
|
|
SI2066694T1
(sl)
|
2006-09-29 |
2016-02-29 |
Oncomed Pharmaceuticals, Inc. |
Sestavki in postopki za diagnosticiranje in zdravljenje raka
|
|
CA3009034C
(en)
|
2006-10-10 |
2020-08-18 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase abci mutants
|
|
FR2918279B1
(fr)
*
|
2007-07-05 |
2010-10-22 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
|
|
CN101575379B
(zh)
*
|
2008-05-09 |
2012-05-30 |
上海抗体药物国家工程研究中心有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
CN102272148A
(zh)
|
2008-11-03 |
2011-12-07 |
分子组合公司 |
抑制vegf-a受体相互作用的结合蛋白
|
|
CN101838329A
(zh)
|
2009-03-18 |
2010-09-22 |
嘉和生物药业有限公司 |
抗血管新生融合蛋白
|
|
TR201818814T4
(tr)
|
2009-10-16 |
2019-01-21 |
Oncomed Pharm Inc |
Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
|
|
PT2601214T
(pt)
|
2010-08-06 |
2017-12-20 |
Genzyme Corp |
Composições de antagonistas de vegf e utilizações destes
|
|
JP6043629B2
(ja)
*
|
2011-01-07 |
2016-12-14 |
中外製薬株式会社 |
抗体の物性を改善させる方法
|
|
BR112013017752A8
(pt)
|
2011-01-13 |
2018-01-09 |
Regeneron Pharma |
uso de um antagonista do vegf e formulação farmacêutica
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
KR101397088B1
(ko)
|
2011-06-10 |
2014-05-19 |
강원대학교산학협력단 |
암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
|
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
AU2012318288B2
(en)
*
|
2011-12-01 |
2015-09-17 |
Ap Biosciences, Inc. |
Protein inhibitors to complement and VEGF pathways and methods of use thereof
|
|
CN103304668B
(zh)
*
|
2012-03-12 |
2015-10-28 |
江苏健德生物药业有限公司 |
Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
|
|
US10568934B2
(en)
|
2012-05-07 |
2020-02-25 |
Allergan, Inc. |
Method of treating AMD in patients refractory to anti-VEGF therapy
|
|
WO2014006113A1
(en)
|
2012-07-03 |
2014-01-09 |
Sanofi |
Method of treating cancer by effective amounts of aflibercept
|
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
|
MY170528A
(en)
|
2013-02-18 |
2019-08-09 |
Vegenics Pty Ltd |
Vegfr-3 ligand binding molecules and uses thereof
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
CN104193828B
(zh)
*
|
2013-09-12 |
2017-04-05 |
北京韩美药品有限公司 |
同时阻断her2和vegfr信号通路的重组融合蛋白
|
|
PT3065761T
(pt)
|
2013-11-05 |
2020-02-21 |
Allergan Inc |
Método de tratamento de condições oculares com um darpin anti-vegf
|
|
EP3492495A1
(en)
|
2014-05-12 |
2019-06-05 |
Formycon AG |
Pre-filled plastic syringe containing a vegf antagonist
|
|
PT3170005T
(pt)
|
2014-07-18 |
2019-07-16 |
Sanofi Sa |
Método para a previsão do resultado de um tratamento com aflibercept de um paciente suspeito de sofrer de um cancro
|
|
JP2016036322A
(ja)
*
|
2014-08-11 |
2016-03-22 |
日本化薬株式会社 |
血管新生因子と結合するキメラタンパク質
|
|
PL3230316T3
(pl)
|
2014-12-11 |
2022-05-02 |
Bayer Healthcare Llc |
Leczenie zwyrodnienia plamki żółtej związanego z wiekiem z małą aktywną zmianą neowaskularyzacji naczyniówki
|
|
GB201503453D0
(en)
|
2015-03-01 |
2015-04-15 |
Jain Arjun |
Endothelin-1"sponge"
|
|
TW202440903A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（一）
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
KR101936049B1
(ko)
*
|
2015-10-15 |
2019-01-08 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 생산방법
|
|
WO2017065559A1
(ko)
|
2015-10-15 |
2017-04-20 |
(주)알테오젠 |
Igg fc 도메인을 가지는 융합 단백질의 생산방법
|
|
CA3005132A1
(en)
|
2015-11-18 |
2017-05-26 |
Sio2 Medical Products, Inc. |
Coated syringe for ophthalmic formulations containing a vegf antagonist
|
|
RU2734958C2
(ru)
|
2015-11-18 |
2020-10-26 |
Формикон Аг |
Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
|
|
WO2017085253A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
|
WO2017084616A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Zhuhai Tairuishang Biopharm Ltd. |
Methods and compositions for binding vegf
|
|
CA3007276C
(en)
|
2015-12-03 |
2021-12-28 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitor to treat macular degeneration in a patient population
|
|
AU2017213103B2
(en)
|
2016-01-26 |
2022-08-11 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
EP3527225A4
(en)
|
2016-10-12 |
2020-06-10 |
Daiichi Sankyo Company, Limited |
COMPOSITION WITH ANTI-ROBO4 ANTIBODIES AND OTHER AGENTS
|
|
JP7116059B2
(ja)
|
2016-11-21 |
2022-08-09 |
ジャスト－エヴォテック バイオロジックス、インコーポレイテッド |
アフリベルセプト製剤及びその使用
|
|
CA3063995A1
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
EP3630043A1
(en)
|
2017-05-24 |
2020-04-08 |
Formycon AG |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
MY199833A
(en)
|
2017-08-17 |
2023-11-24 |
Just Evotec Biologics Inc |
Method of purifying glycosylated protein from host cell galectins and other contaminants
|
|
JP7183268B2
(ja)
|
2017-11-20 |
2022-12-05 |
ジャスト－エヴォテック バイオロジックス、インコーポレイテッド |
等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
|
|
PT3717636T
(pt)
|
2017-11-27 |
2023-05-30 |
4D Molecular Therapeutics Inc |
Cápsides variantes de vírus adeno-associado e utilização para inibir a angiogénese
|
|
EP3716992B1
(en)
|
2017-11-30 |
2022-08-10 |
Regeneron Pharmaceuticals, Inc. |
Use of a vegf antagonist to treat angiogenic eye disorders
|
|
WO2019118187A1
(en)
|
2017-12-13 |
2019-06-20 |
Regeneron Pharmaceuticals, Inc. |
Devices and systems for chromatography column bed support management and related methods
|
|
SG11202007130RA
(en)
|
2018-01-26 |
2020-08-28 |
Univ California |
Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
|
|
CN112203679A
(zh)
|
2018-03-02 |
2021-01-08 |
科达制药股份有限公司 |
Il-6抗体及其融合构建体和缀合物
|
|
TW202016125A
(zh)
*
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
BR112020022610A2
(pt)
|
2018-05-10 |
2021-02-09 |
Regeneron Pharmaceuticals, Inc. |
proteína de fusão de receptor de vegf de alta concentração que contém formulações
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
CN111378044B
(zh)
|
2018-12-28 |
2022-07-15 |
长春金赛药业有限责任公司 |
抗体融合蛋白、制备方法及其应用
|
|
EP3969564A1
(en)
|
2019-05-16 |
2022-03-23 |
Formycon AG |
Method for reducing methionine oxidation in recombinant proteins
|
|
MX2022002355A
(es)
|
2019-09-03 |
2022-04-06 |
Amgen Inc |
Dispositivo de inyeccion para suministro de farmacos y envase para el dispositivo de inyeccion.
|
|
CA3150482A1
(en)
|
2019-09-16 |
2021-03-25 |
Amgen Inc. |
Method for external sterilization of drug delivery device
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CA3168512A1
(en)
|
2019-11-25 |
2021-06-03 |
Napoleone Ferrara |
Long-acting vegf inhibitors for intraocular neovascularization
|
|
US11186625B2
(en)
|
2019-12-06 |
2021-11-30 |
Regeneran Pharmaceuticals, Inc. |
Anti-VEGF protein compositions and methods for producing the same
|
|
US20230063116A1
(en)
|
2019-12-06 |
2023-03-02 |
Regeneron Pharmaceuticals, Inc. |
Vegf mini-traps and method of use thereof
|
|
US12240652B2
(en)
|
2020-02-24 |
2025-03-04 |
Amgen Inc. |
Containers and systems for use during external sterilization of drug delivery devices
|
|
AU2021268026A1
(en)
|
2020-05-08 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
VEGF traps and mini-traps and methods for treating ocular disorders and cancer
|
|
US12472148B2
(en)
|
2021-04-26 |
2025-11-18 |
Celanese Eva Performance Polymers Llc |
Implantable device for sustained release of a macromolecular drug compound
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
WO2023092324A1
(zh)
|
2021-11-24 |
2023-06-01 |
苏州光度生物科技有限公司 |
多特异性配体结合分子及其应用
|
|
JP2025530910A
(ja)
|
2022-08-02 |
2025-09-18 |
パノロスバイオサイエンスインク |
修飾された融合タンパク質及びその用途
|
|
KR20250065646A
(ko)
|
2022-09-16 |
2025-05-13 |
치루 파머수티컬 컴퍼니 리미티드 |
안정적인 고농도 자가완충식 약물 조성물
|
|
WO2025033876A1
(ko)
*
|
2023-08-04 |
2025-02-13 |
주식회사 파노로스바이오사이언스 |
변형된 융합 단백질과 scFv의 결합체 및 이의 용도
|
|
WO2025213011A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Method of assessing stopper movement in a drug delivery device
|